Skip to content
DataLookout
Menu

NCT07397728

" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 7 words
    • Trial completed
    • Final enrollment: 180 participants (planned 90)
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Systemic Lupus Erythematosus Assessment
Timeframe: 3 Months
TREX1 gene polymorphism and SLE
Timeframe: 3 Months

Arms and interventions

Group A : (Systemic Lupus Erythrematosus)

About 90 patients diagnosed with SLE based on 2019 EULAR/ACR criteria, each with at least one cutaneous manifestation.

Group B (Healthy Controls)

90 age- and sex-matched healthy controls with no personal or family history of autoimmune disease and negative ANA and anti-dsDNA.

Diagnostic tests: TREX1 gene polymorphisms

Sites

1 site in 1 country

  • Qina University hospital, South Valley University HospitalQina, South Valley, Egypt